These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 10316797)

  • 21. Implementation of the mutual recognition agreement between the United States and the European Community; pharmaceutical GMP's and medical devices; establishment of a public docket and FDA contact points. Food and Drug Administration, HHS. Establishment of a public docket and FDA contact points.
    Fed Regist; 1999 Mar; 64(45):11376-7. PubMed ID: 10557625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Getting SMART (submission management and review tracking) drug review in the computer age.
    Flieger K
    FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 25. FDA electronic drug labels to improve patient safety.
    J Pain Palliat Care Pharmacother; 2006; 20(2):96-7. PubMed ID: 16789334
    [No Abstract]   [Full Text] [Related]  

  • 26. A drug problem reporting system for Canadian hospital pharmacies.
    Friedel H; Gibson C
    Can J Hosp Pharm; 1978; 31(6):205-6. PubMed ID: 10240006
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug defect reporting program.
    Valentino JG
    Bull Parenter Drug Assoc; 1975; 29(2):55-63. PubMed ID: 1120213
    [No Abstract]   [Full Text] [Related]  

  • 28. A drug defect reporting programme.
    Marigold W
    Can J Hosp Pharm; 1977; 30(5):140-1. PubMed ID: 10316502
    [No Abstract]   [Full Text] [Related]  

  • 29. Planning for change.
    Hansen DC
    Bull Parenter Drug Assoc; 1969; 23(1):1-5. PubMed ID: 5765717
    [No Abstract]   [Full Text] [Related]  

  • 30. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 31. The patient information and education initiative.
    Rheinstein PH; McGinnis TJ; Nightingale SL
    Am Fam Physician; 1995 Dec; 52(8):2377-8, 2381-2. PubMed ID: 7484726
    [No Abstract]   [Full Text] [Related]  

  • 32. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
    Williams RL; ;
    J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse reaction reporting program.
    Knobloch CP
    J Am Vet Med Assoc; 1980 Jan; 176(1):29. PubMed ID: 6892526
    [No Abstract]   [Full Text] [Related]  

  • 34. Prescription and proscription.
    Ingelfinger FJ; Elia JJ
    N Engl J Med; 1971 Nov; 285(21):1199-201. PubMed ID: 5096644
    [No Abstract]   [Full Text] [Related]  

  • 35. The drug efficacy study.
    Provost GP
    Am J Hosp Pharm; 1968 Sep; 25(9):483. PubMed ID: 5671558
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 37. The drug-potency question.
    Walker JM
    US Navy Med; 1974 Aug; 64(2):26-30. PubMed ID: 4534296
    [No Abstract]   [Full Text] [Related]  

  • 38. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
    Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805
    [No Abstract]   [Full Text] [Related]  

  • 39. Providing drug information to health professionals and consumers: role and responsibility of the pharmaceutical manufacturer.
    Boyland JI
    Hosp Pharm; 1983 Apr; 18(4):211-3, 216. PubMed ID: 10260207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public standards for drugs: reflections on their use by the professions and industry.
    Miller LC
    Hosp Formul; 1976 Mar; 11(3):151-5. PubMed ID: 1026682
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.